• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

肌层浸润性膀胱癌患者的新辅助化疗：哪些患者受益？

Neoadjuvant chemotherapy in patients with muscle-invasive bladder cancer: which patients benefit?

机构信息

Department of Urology, Heinrich-Heine-University, Düsseldorf, Germany.

出版信息

Eur Urol. 2013 Sep;64(3):355-7. doi: 10.1016/j.eururo.2013.06.002. Epub 2013 Jun 12.

DOI:10.1016/j.eururo.2013.06.002
PMID:23773558
Abstract

Level I evidence supports neoadjuvant chemotherapy in the treatment of advanced bladder cancer. For the most benefit, it is suggested that neoadjuvant chemotherapy be restricted to patients with clinical T3 disease and/or clinical N+ disease.

摘要

一级证据支持新辅助化疗治疗晚期膀胱癌。为了获得最大益处，建议将新辅助化疗仅限于临床 T3 疾病和/或临床 N+疾病患者。

相似文献

1
Neoadjuvant chemotherapy in patients with muscle-invasive bladder cancer: which patients benefit?肌层浸润性膀胱癌患者的新辅助化疗：哪些患者受益？
Eur Urol. 2013 Sep;64(3):355-7. doi: 10.1016/j.eururo.2013.06.002. Epub 2013 Jun 12.
2
Treatment of muscle-invasive and metastatic bladder cancer: update of the EAU guidelines.肌层浸润性和转移性膀胱癌的治疗：EAU 指南更新。
Eur Urol. 2011 Jun;59(6):1009-18. doi: 10.1016/j.eururo.2011.03.023. Epub 2011 Mar 23.
3
Long-term outcomes of selective bladder preservation by combined-modality therapy for invasive bladder cancer: the MGH experience.联合治疗浸润性膀胱癌保膀胱的长期疗效：MGH 经验。
Eur Urol. 2012 Apr;61(4):705-11. doi: 10.1016/j.eururo.2011.11.010. Epub 2011 Nov 12.
4
Pathologic downstaging is a surrogate marker for efficacy and increased survival following neoadjuvant chemotherapy and radical cystectomy for muscle-invasive urothelial bladder cancer.病理降期是新辅助化疗和根治性膀胱切除术治疗肌层浸润性尿路上皮膀胱癌后疗效和生存率提高的替代标志物。
Eur Urol. 2012 Jun;61(6):1229-38. doi: 10.1016/j.eururo.2011.12.010. Epub 2011 Dec 13.
5
Correlation of pathologic complete response with survival after neoadjuvant chemotherapy in bladder cancer treated with cystectomy: a meta-analysis.膀胱癌行根治性膀胱切除术的新辅助化疗后病理完全缓解与生存的相关性：一项荟萃分析。
Eur Urol. 2014 Feb;65(2):350-7. doi: 10.1016/j.eururo.2013.06.049. Epub 2013 Jul 3.
6
Use of potentially curative therapies for muscle-invasive bladder cancer in the United States: results from the National Cancer Data Base.美国肌肉浸润性膀胱癌潜在治愈疗法的使用：来自国家癌症数据库的结果。
Eur Urol. 2013 May;63(5):823-9. doi: 10.1016/j.eururo.2012.11.015. Epub 2012 Nov 19.
7
Neoadjuvant chemotherapy in patients with invasive bladder cancer.浸润性膀胱癌患者的新辅助化疗
Urol Clin North Am. 2005 May;32(2):231-7. doi: 10.1016/j.ucl.2005.03.001.
8
NCCN Guidelines Insights: Bladder Cancer, Version 5.2018.NCCN 指南解读：膀胱癌，第 5 版 2018 年
J Natl Compr Canc Netw. 2018 Sep;16(9):1041-1053. doi: 10.6004/jnccn.2018.0072.
9
Retrospective analysis of the efficacy of two cycles of M-VAC neoadjuvant chemotherapy followed by radical cystectomy for muscle-invasive bladder cancer.回顾性分析两周期 M-VAC 新辅助化疗后行根治性膀胱切除术治疗肌层浸润性膀胱癌的疗效。
Anticancer Res. 2013 Oct;33(10):4497-503.
10
Integration of neoadjuvant and adjuvant chemotherapy and cystectomy in the treatment of muscle-invasive bladder cancer.新辅助化疗与辅助化疗及膀胱切除术在肌层浸润性膀胱癌治疗中的整合
BJU Int. 2008 Nov;102(9 Pt B):1339-44. doi: 10.1111/j.1464-410X.2008.07980.x.

引用本文的文献

1
Prospective Evaluation of FDG-PET/CT for On-treatment Assessment of Response to Neoadjuvant or Induction Chemotherapy in Invasive Bladder Cancer.18F-氟脱氧葡萄糖正电子发射断层扫描/计算机断层扫描对浸润性膀胱癌新辅助或诱导化疗反应的治疗中评估的前瞻性研究
Bladder Cancer. 2023 Mar 31;9(1):49-57. doi: 10.3233/BLC-220036. eCollection 2023.
2
Patient-Reported Outcomes, Health-Related Quality of Life, and Clinical Outcomes for Urothelial Cancer Patients Receiving Chemo- or Immunotherapy: A Real-Life Experience.接受化疗或免疫治疗的尿路上皮癌患者的患者报告结局、健康相关生活质量和临床结局：一项真实生活经验
J Clin Med. 2021 Apr 24;10(9):1852. doi: 10.3390/jcm10091852.
3
Role of Microtubule-Associated Protein 1b in Urothelial Carcinoma: Overexpression Predicts Poor Prognosis.
微管相关蛋白1b在尿路上皮癌中的作用：过表达预示预后不良。
Cancers (Basel). 2020 Mar 9;12(3):630. doi: 10.3390/cancers12030630.
4
Patient-reported outcomes item selection for bladder cancer patients in chemo- or immunotherapy.化疗或免疫治疗中膀胱癌患者的患者报告结局指标选择
J Patient Rep Outcomes. 2019 Aug 22;3(1):56. doi: 10.1186/s41687-019-0141-2.
5
Should we spare neoadjuvant chemotherapy in low-risk muscle-invasive bladder cancer patients scheduled for radical cystectomy?对于计划进行根治性膀胱切除术的低风险肌层浸润性膀胱癌患者，我们是否应省去新辅助化疗？
Transl Androl Urol. 2019 Jul;8(Suppl 3):S283-S286. doi: 10.21037/tau.2019.04.04.
6
A three-gene methylation marker panel for the nodal metastatic risk assessment of muscle-invasive bladder cancer.用于肌层浸润性膀胱癌淋巴结转移风险评估的三基因甲基化标志物panel。
J Cancer Res Clin Oncol. 2019 Apr;145(4):811-820. doi: 10.1007/s00432-018-02829-4. Epub 2019 Jan 2.
7
A Festschrift in Honor of Edward M. Messing, MD, FACS.献给医学博士、美国外科医师学会会员爱德华·M·梅西的纪念文集。
Bladder Cancer. 2018 Oct 3;4(Suppl 1):S1-S43. doi: 10.3233/BLC-189037.
8
New discoveries in the molecular landscape of bladder cancer.膀胱癌分子格局的新发现。
F1000Res. 2016 Dec 19;5:2875. doi: 10.12688/f1000research.10031.1. eCollection 2016.
9
The Emergence of Precision Urologic Oncology: A Collaborative Review on Biomarker-driven Therapeutics.精准泌尿外科肿瘤学的兴起：关于生物标志物驱动治疗的协作性综述
Eur Urol. 2017 Feb;71(2):237-246. doi: 10.1016/j.eururo.2016.08.024. Epub 2016 Aug 25.
10
BcCluster: A Bladder Cancer Database at the Molecular Level.BcCluster：一个分子水平的膀胱癌数据库。
Bladder Cancer. 2016 Jan 7;2(1):65-76. doi: 10.3233/BLC-150024.